JY
DFTX

Jeff Yass’s Definium Therapeutics DFTX Stock Holding History

Jeff Yass’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.2M Buy
471,000
+254,800
+118% +$6.3M ﹤0.01% 2348
2026
Q1 		$4.09M Buy
216,200
+83,600
+63% +$1.42M ﹤0.01% 4618
2025
Q4 		$1.78M Sell
132,600
-113,200
-46% -$1.4M ﹤0.01% 5893
2025
Q3 		$2.9M Buy
245,800
+115,900
+89% +$1.08M ﹤0.01% 5044
2025
Q2 		$843K Buy
129,900
+49,900
+62% +$328K ﹤0.01% 7886
2025
Q1 		$468K Sell
80,000
-30,700
-28% -$220K ﹤0.01% 9041
2024
Q4 		$770K Buy
110,700
+20,300
+22% +$140K ﹤0.01% 7601
2024
Q3 		$514K Sell
90,400
-33,900
-27% -$236K ﹤0.01% 8399
2024
Q2 		$896K Buy
124,300
+20,800
+20% +$182K ﹤0.01% 6852
2024
Q1 		$973K Buy
103,500
+23,900
+30% +$136K ﹤0.01% 6982
2023
Q4 		$291K Buy
79,600
+24,800
+45% +$74.7K ﹤0.01% 9909
2023
Q3 		$172K Sell
54,800
-1,100
-2% -$4.52K ﹤0.01% 10401
2023
Q2 		$200K Buy
55,900
+17,600
+46% +$60.7K ﹤0.01% 10275
2023
Q1 		$121K Sell
38,300
-66,400
-63% -$221K ﹤0.01% 11115
2022
Q4 		$230K Sell
104,700
-201,200
-66% -$559K ﹤0.01% 9774
2022
Q3 		$1.07M Buy
305,900
+282,240
+1,193% +$2.71M ﹤0.01% 6469
2022
Q2 		$227K Sell
23,660
-10,813
-31% -$137K ﹤0.01% 10314
2022
Q1 		$574K Sell
34,473
-14,707
-30% -$255K ﹤0.01% 8620
2021
Q4 		$1.02M Buy
49,180
+1,607
+3% +$51.3K ﹤0.01% 7245
2021
Q3 		$1.66M Buy
47,573
+7,113
+18% +$308K ﹤0.01% 6237
2021
Q2 		$2.09M Buy
+40,460
New +$2.12M ﹤0.01% 5813

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Jeff Yass's DFTX Position: Q2 2026 in Review

Jeff Yass reduced its Definium Therapeutics (DFTX) stake by 50% in Q2 2026, selling an estimated $1M and leaving 40,954 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #6559.

Jeff Yass first reported a position in DFTX in Q2 2021 and has held it in 17 quarters since. The position peaked at $6.39M in Q4 2025. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Jeff Yass held 40,954 shares of Definium Therapeutics worth $1.93M as of Q2 2026.
  • Jeff Yass sold 40,502 Definium Therapeutics shares in Q2 2026, an estimated $1M.
  • Definium Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #6559 holding.
  • Jeff Yass first reported a position in Definium Therapeutics in Q2 2021 and has held it in 17 quarters since.
  • Jeff Yass's Definium Therapeutics position peaked at $6.39M in Q4 2025.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.